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Abstract 
Identification of genes in oncogenic chromosome translocations by Fluorescence In Situ Hybridization (FISH) screening 
using genomic tilepath clones, is often laborious, notably if the region of interest is gene-dense. Other molecular 
methods for partner identification also suffer limitations; for instance, genomic PCR screening requires prior knowledge 
of both sets of breakpoints, while Rapid Amplification of cDNA Ends (RACE) is limited to translocations causing 
mRNA fusion and delivers no breakpoint data. With Long Distance Inverse (LDI)-PCR, however, it is possible to 
identify unknown translocation partners and to map breakpoints at the base-pair level. Applying LDI-PCR merely 
requires approximate sequence information on one partner, rendering it ideal for use in combination with FISH to 
extend and refine cytogenetic breakpoint data.  
 
Introduction 
Recurrent chromosomal rearrangements characterize 
many different types of cancer.  
Specific cytogenetic translocations are key events, 
widely considered to be diagnostically and 
prognostically significant in leukemia and lymphoma, 
and increasingly so in solid tumors (Mitelman et al., 
2007). Hitherto, most cancer genes have been identified 
following analysis of recurrent chromosome 
translocations (Futreal et al., 2004). The pathological 
significance and usefulness of such rearrangements 
depend on two key features: a) whether rearrangements 
display distinct patterns of recurrence within specific 
tumors, e.g. t(8;14)(q24;q32) which is restricted to B-
cell neoplasia; and b) how clustered are the 
chromosomal breakpoints therein. The significance 
accorded to breakpoint data depends on their 
ascertainment precision, from megabase- and kilobase-, 
down to single base-pair levels, when ascertained by 
classical cytogenetics, fluorescence in situ 
hybridization (FISH), and sequence-based methods, 
respectively.  
Chromosome translocations fall into three broad 
categories. The first causes the physical fusion of the 
two mRNAs expressed by the participating genes, thus 
creating novel fusion proteins translated from exons 
emanating from both genes, e.g. BCR (at 
[chromosome]-22-[band]-q11) with ABL1 (at 9q34) 
fused by t(9;22)(q34;q11) in chronic myeloid leukemia 
(CML) and in some cases of acute lymphoblastic 
leukemias (ALL) (Turhan, 2008a,b). The second 
category also fuses mRNA from genes at separate loci 
but, in this case, serving to deregulate a 
developmentally silenced partner by exchanging 
promoters with more active partners, e.g. BCL6 (at 
3q27) which is activated by translocations with any one 
of many partners, chiefly in diffuse large B-cell 
lymphoma (DLBCL) (Knezevich, 2007).  
The third class of chromosome translocation again 
results in the activation of the normally silent partner, 
this time by juxtaposition with another constitutively 
active partner without mRNA fusion, e.g. the 
neighboring homeobox genes, TLX3 (at 5q35.1) and 
NKX2-5 (at 5q35.2). According to the proximity of the 
breakpoint involved, either (but not both) genes may be 
activated in T-cell ALL by the recurrent 
t(5;14)(q35;q32.2) by which these are juxtaposed with 
regulatory regions from BCL11B (at 14q32.2) to 
stimulate transcription (Bernard et al., 2001; MacLeod 
et al., 2003; Nagel et al., 2007). 
Some "promiscuous" genes engage with multiple 
partners: notably MLL with 64 known partners (Meyer 
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et al., 2009b), BCL6 with 28 (Knezevich, 2007), 
RUNX1 with 39 (Huret and Senon, 2003), NUP98 with 
29 (Kearney, 2002), and the IgH-locus with 40 
(Lefranc, 2003).  
Although, promiscuity may reflect the dependence of 
tumors on the inappropriate oncogene expression 
without overly caring how deregulation is 
accomplished, the role of the partner genes has come 
under renewed scrutiny. Choice of partner gene may 
not only reveal in which types of precancerous cells 
primary oncogenic rearrangements occur, but also by 
looking for conserved DNA or protein motifs, yield 
clues to the mechanisms underlying their formation or 
their functional contribution to neoplasia. In addition, 
the roles of biologically important genes, e.g. BCL11B, 
a key regulator of both differentiation and survival 
during thymocyte development, are often first rendered 
visible by their participation in cancer rearrangements 
(MacLeod et al., 2003). 
Both the identities of each partner gene and their 
precise breakpoints at the DNA base-pair level, may be 
useful not only to characterize potential fusion 
genes/products but also to ascertain whether additional 
non protein-coding genomic entities, such as 
chromosomal fragile sites (Schneider et al., 2008), 
microRNA loci, putative genes, unspliced "expressed 
sequence tags", or regulatory non-coding regions may 
be involved.  
Clues to the biological mechanisms generating 
chromosome rearrangements are given by breakpoint 
sequences, including T- and B-cell receptor gene (VDJ) 
rearrangement, Alu-mediated recombination, non-
homologous end joining, etc. VDJ genes are flanked by 
recombination signal sequences composed of 
heptamers followed, in turn, by a spacer containing 
either 12 or 23 unconserved nucleotides and a 
conserved nonamer. Spacers of 12 nucleotides undergo 
physiological recombination with those containing 23 
in order to obey the so-called "12/23 rule". The 
presence of these or related sequences has been 
reported in connection with cancer translocations to 
reveal how physiologic processes may be abused to 
cause genomic rearrangements (Gu et al., 1992). 
Genomic fusion sequences may also be used to aid cell 
line authentication - an omnipresent problem 
confronting cell culturists, given that an unexpectedly 
(and unacceptably) high percentage of new cell lines 
has been misidentified, or cross-contaminated by older 
cell lines (MacLeod et al., 1999). While mRNA fusion 
sequences are constrained by splicing, their genomic 
equivalents allow sufficient variation to provide 
"fingerprints" unique to individual cell lines to serve as 
potential identifiers. For analyzing patient tumors, 
knowledge of the exact fusion sequence allows design 
of patient-specific quantitative (q)PCR used for 
monitoring minimal residual disease with high 
sensitivity (Burmeister et al., 2006), to follow up 
therapeutic responses thus enabling early detection of 
relapse. 
 
Figure 1: Amplifying Genomic Fusions of Unknown Sequence. The schema summarizes how the genomic DNA is first restricted, then re-
ligated to the circular template, and how the resulting amplicon should appear. Note unknown region (red) flanked by known sequences 
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Cancer gene promiscuity enables oncogenic 
chromosome rearrangements, "smoking guns" of 
cancer genes, to be distinguished from random 
changes. FISH is initially used to confirm 
rearrangement of a contextually appropriate oncogene 
residing at the locus in question. Hence, a breakpoint at 
9q34 might throw suspicion onto NOTCH1 in a T-cell-, 
ABL1 in myeloid- neoplasia, and NUP214 in either 
entity. While such an approach is less helpful among 
solid tumors where oncogene rearrangements are less 
informative, at this locus TSC1 might be deemed a 
candidate in tuberous sclerosis cells. Even when the 
index breakpoint is precisely known, determination of 
its partner by FISH requires time-consuming and 
laborious procedures for those not afforded immediate 
blanket tilepath-clone coverage with which to quarter 
the region of interest.  
PCR screening with hit-lists of known and potential 
partner genes is quite as laborious as FISH, and is 
liable to miss unknown translocation partners, or those 
with breakpoints lying outside their respective cluster 
regions. When there are grounds to suspect 
transcriptional fusion (as among partners of genes 
prone to this type of gene rearrangement, e.g. ABL1, 
ETV6, NUP98, etc.) a mRNA-based method, rapid 
amplification of cDNA ends (RACE), may be used to 
detect novel fusion partners (Frohman et al., 1988). A 
drawback of RACE is its inability to supply genomic 
breakpoint data, and the risk of overlooking some 
splice variants. Hence, the technique of choice for 
identifying unknown partner genes and their 
breakpoints should not require prior knowledge of the 
partner gene, yet provide breakpoint data at the DNA 
base pair level. 
Long Distance Inverse (LDI)-PCR satisfies these 
needs. LDI-PCR was developed from the earlier 
inverse-PCR (Ochman et al., 1988) to allow the 
amplification of large DNA fragments comprised of 
known and unknown sequences (Willis et al., 1997) 
using re-ligated circular restriction fragments as 
templates. Primers are set in opposition within the 
known sequence. The unknown sequence is flanked on 
both sides by known sequences following re-ligation in 
the resultant amplicon (Fig. 1). When a restriction 
fragment length polymorphism (RFLP) distinguishing 
the wild type and derivative alleles is generated by the 
genomic alteration, the two resulting amplicons should 
be separable by gel electrophoresis, enabling their 
respective sequences to be compared (Fig. 2). 
Sequencing with one of the PCR-primers directed 
towards the restriction site allows immediate 
identification of the partner gene. Sequencing in the 
other direction allows precise mapping of the 
breakpoint.  
 
Figure 2: How to Interpret LDI-PCR Gels. Left figure shows the wild type configuration where twin circular templates identical in size 
would yield a single band by agarose gel electrophoresis. Translocation bearing cells (right figure) yield both wild type and derivative 
templates, differing in size and detectible as two bands on the gel. The derivative band is indicated by an arrow. Known regions are 
outlined in black, unknown in red. R: Restriction site, REV: reverse primer, FW: forward primer.  
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While easier to perform for genes with well defined, 
short breakpoint cluster regions, LDI-PCR may be 
applied to any gene or region involved in a 
translocation and has, therefore, been applied to a wide 
variety of translocations involving both frequently 
rearranged promiscuous oncogenes, but also as single 
events. Table 1 gives an overview of genes analyzed by 
LDI-PCR according to literature databases and the 
respective references. 
Limitations are set by the performance of the DNA 
polymerase since lengthier fragments may resist 
amplification, and by the placement of the RFLP, as 
fragments similar in size cannot be readily 
distinguished by gel electrophoresis. If primary patient 
tumor material is analyzed, it should be noted that the 
samples used for analysis not only contain tumor 
material, but also normal bystander cells devoid of 
tumor rearrangement. Detection attempted at lower 
tumor infiltration rates risk false negative results. 
In contrast to other PCR methods suitable for detection 
of unknown fusion sequences, such as panhandle PCR 
(Megonigal et al., 2000) or analogous techniques 
requiring adaptor ligations (reviewed in Tonooka and 
Fujishima, 2009), LDI-PCR is independent of any 
additional adaptors or anchors which have to be ligated 
to the restricted fragments, reducing the number of 
steps required, while remaining sufficiently flexible to 
allow a wide choice of restriction enzymes. 
In the future, translocation analysis by next generation 
sequencing should overcome these limitations and 
suitable algorithms have been developed to recognize 
novel derivative breakpoint-flanking sequences and 
thereby identify novel cancer translocations and other 
synonymous rearrangements, including a subset of 
fusogenic microdeletions (Campbell et al., 2008). 
Methology 
In principle, LDI-PCR utilizes digested and re-ligated 
circular templates, which are of different sizes, due to 
RFLP caused by genomic rearrangements. This size 
difference renders the amplicons separable by gel 
electrophoresis (Fig. 2). 
For a successful analysis, the LDI-PCR has to be 
designed carefully. The sequence covering the genomic 
region of interest should be selected from a genome 
browser (ENSEMBL, UCSC, NCBI) and then pasted 
into the query box of a restriction map generator 
(BioEdit, multiple online tools: SMS, 
RestrictionMapper). Restriction enzymes should be 
chosen to yield fragments in a size range of 2-5 kb. If 
using a double-digest strategy with enzymes producing 
sticky ends, these ends must be compatible. Ensure that 
both enzymes perform well in the same buffer and at 
the same temperature. Primer pairs have to be designed 
in such a way that one primer is directed towards the 
restriction site, the other one in the opposite direction 
(see Figures). The sequence lying between the primer 
tails is not subject to amplification, so the gap should 
not be excessive, ideally 30-50 bp. A breakpoint lying 
therein cannot be detected unless another primer pair, 
e.g. at the other end of the restriction fragment is used. 
For longer fragments (greater than 5 kb, say) use of a 
primer set consisting of one forward and multiple 
reverse primers (or vice versa) can be helpful. The 
oligonucleotides should be ~30 bp with a Tm ~65°C 
and a GC-content of 40-60%. 
For LDI-PCR template preparation high quality 
genomic DNA should be used, meaning high purity 
(260/280 1.8-2.0 and 260/230 > 2) and high integrity 
without degradation. One microgram of DNA is then 
digested with 30-50 U of each restriction enzyme in the 
presence of the appropriate digestion buffer in a total 
volume of 100 μl for 3-4 h at the temperature suitable 
for the chosen enzymes (mostly 37°C), followed by 
heat inactivation (where applicable) and purification, 
preferably with a column based purification kit. Phenol 
/ chloroform purification followed by precipitation may 
also be performed, but residual phenol can disturb 
downstream processes. To form the circular templates, 
the restriction fragments are then religated with 5 U T4 
ligase overnight at 4-8°C in a total volume of 80 μL, 
terminated by heat inactivation. These conditions favor 
the desired self-ligation. 
The PCR is performed best using a PCR kit suitable for 
amplification of long templates and using 5 μL (62.5 
ng) of the digested and re-ligated DNA. The PCR 
products are analyzed by gel electrophoresis. 
Discrepant bands not corresponding to the calculated 
amplicon size may represent amplicons of translocated 
fragments. These are excised from the gel, purified and 
subjected to sequence analysis and, unless artefacts, 
may reveal the translocation partner and the exact 
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Gene No. of Partners References describing LDI-PCR analysis 
ALK 14 (Allouche, 2010) Ma et al., 2000 
ANTXR1 1 (Oberthuer et al., 2005) Oberthuer et al., 2005 
API2 1 (Mathijs and Marynen, 2001) Dierlamm et al., 1999 
BCL6 28 (Knezevich, 2007) 
Akasaka H et al., 2000; Akasaka T et al., 2000; Kurata et 
al., 2002; Akasaka et al., 2003; Chen et al., 2003; 
Montesinos-Rongen et al., 2003; Chen et al., 2006; 
Schneider et al., 2008 
BRD4 1 (Collin, 2007) Haruki et al., 2005 
CALL 1 (Frints et al., 2003) Frints et al., 2003 
E2A 5 (Huret, 1997) Wiemels et al., 2002a 
ETV6 28 (Knezevich, 2005) 
Wiemels et al., 1999a; Wiemels et al., 1999b; Wiemels 
and Greaves, 1999; Wiemels et al., 2008 
IGH 40 (Lefranc, 2003) 
Willis et al., 1997; Willis et al., 1998; Nardini et al., 2000; 
Satterwhite et al., 2001; Sonoki et al., 2001; Bichi et al., 
2002; Sanchez-Izquierdo et al., 2003; Sonoki et al., 2004; 
Akasaka et al., 2007; Lenz et al., 2007; Souabni et al., 
2007; d'Amore et al., 2008; Ishizaki et al., 2008; Russell et 
al., 2008; Vieira et al., 2008; Vinatzer et al., 2008; Nagel 
et al., 2009; Russell et al., 2009; Yin et al., 2009; Hu et al., 
2010 
let-7a-2, miR-100 1 (Bousquet, 2008) Bousquet et al., 2008 
MLH1 1 (Meyer et al., 2009b) Meyer et al., 2009a 
MLL 64 (Meyer et al., 2009b) 
Blanco et al., 2001; Meyer et al., 2005; Teuffel et al., 
2005; Attarbaschi et al., 2006; Burmeister et al., 2006; 
Matsuda et al., 2006; Meyer et al., 2006a; Meyer et al., 
2006b; Strehl et al., 2006; Burmeister et al., 2008; 
Balgobind et al., 2009; Bueno et al., 2009; Burmeister et 
al., 2009; Matsuda et al., 2009; Meyer and Marschalek, 
2009; Cóser et al., 2010; De Braekeleer et al., 2010; Lee et 
al., 2010 
NOTCH1 2 (Suzuki et al., 2009) Suzuki et al., 2009 
PAX5 6 (Strehl, 2005) An et al., 2008; An et al., 2009 
PDGFRA 6 (Dessen, 2009) Cools et al., 2003 
PDGFRB 20 (Vizmanos, 2005) Walz et al., 2007; Walz et al., 2009 
RUNX1 / AML1 39 (Huret and Senon, 2003) Xiao et al., 2001; Wiemels et al., 2002b 
Table 1: Genes involved in translocations analyzed by LDI-PCR, numbers of yet known translocation partner genes and references 
wherein the analysis of the particular gene is described. 
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